Marcello Giagheddu
University of Cagliari
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marcello Giagheddu.
Brain Research | 1995
Francesco Marrosu; Chiara Portas; Maria Stefania Mascia; Maria Antonietta Casu; Mauro Fà; Marcello Giagheddu; Assunta Imperato; Gian Luigi Gessa
The variations of Acetylcholine (ACh) release in the cerebral cortex and dorsal hippocampus were monitored by microdialysis during the electroencephalographically recorded sleep-waking cycle in freely moving cats. The results show a state-dependent variation in ACh output in both the cortex and the hippocampus. ACh release increased by approximately 100% during quiet waking (QW) and by 175% during active waking (AW) as referred to slow wave sleep (SWS) baseline. In contrast, a clear difference between the two areas was observed during REM sleep. During this stage ACh release in the cortex reached approximately the same values observed during QW, while in the hippocampus ACh release rose to about 4-fold the level obtained during SWS or twice that of QW. The results support the idea that the increase in ACh release in the cortex reflects the desynchronized EEG of wakefulness and REM sleep, while the marked increase of ACh during REM in the hippocampus may be related to the sustained theta activity in this area.
Acta Neurologica Scandinavica | 1983
Marcello Giagheddu; G. Puggioni; C. Masala; F. Biancu; G. Pirari; M. R. Piras; M. G. Rachele
ABSTRACT From 1957 to 1980 in Sardinia, 182 cases of ALS with a mean annual incidence of 0.51 per 100,000 inhabitants and a prevalence rate of 3.65 per 100,000 inhabitants (prevalence day 21.10.1971) were observed. The disease was found to be more common in males, in subjects aged 50 to 70 years and in farmers and shepherds. Incidence in various areas of the island was found to be different. The common form was more frequent, had earlier onset and greater median survival rate.
Brain Research | 1990
Francesco Marrosu; Gian Luigi Gessa; Marcello Giagheddu; Walter Fratta
The intracerebroventricular injection (1 microgram) of murine corticotropin-releasing factor (r-CRF) to rats after 72 h of sleep deprivation markedly postponed the sleep onset, reduced slow wave sleep and prolonged the duration of paradoxical sleep (PS) episodes. Moreover, CRF is-to our knowledge-the first compound to be able to further prolong PS in a condition (sleep deprivation) in which its duration is already increased. Our findings raise the possibility that CRF might play a physiological role in the regulation of the sleep-wakefulness cycle.
Epilepsia | 1988
Francesco Marrosu; Walter Fratta; Paolo Carcangiu; Marcello Giagheddu; Gian Luigi Gessa
Summary: Murine corticotropin releasing factor (rCRF), injected intracerebroventricularly into rats at a dose of 10 |Ag produced increased motor activity, grooming, and recurrent episodes of epileptic activity localized in the hippocampal leads. Such activity persisted for ˜5 h and was characterized by recurrent trains of biphasic spikes never associated with behavioral signs of epilepsy. The intraperitoneal administration of carbamazepine (15 and 30 mg/kg) reduced the epileptic activity for ˜90 and 120 min, respectively, whereas that of naloxone (8 mg/kg) was ineffective. The results suggest that rCRF‐induced spiking activity might be a model of temporal lobe epilepsy.
Acta Neurologica Scandinavica | 2001
Marcello Giagheddu; Giorgio Tamburini; Mario Piga; Paolo Tacconi; Antonio Giagheddu; Alessandra Serra; P Siotto; Loredana Satta; Luigi Demelia; Francesco Marrosu
Objectives – The purpose of this study is to evaluate the efficiency of a few methodologies in detecting anatomo‐functional brain abnormalities in patients with Wilsons disease. Materials and methods – Twenty‐three patients with Wilsons disease underwent almost simultaneously brain magnetic resonance imaging (MRI), computerized electroencephalography (EEG), multimodal evoked potentials (EPs) and ECD single photon computerized tomography (SPECT) evaluation. The clinical picture was of the neurologic type in 8 patients and of the hepatic type in 15. Results – MRI was abnormal in 7 patients with neurological manifestations. The EPs proved pathologic in 7 neurologically symptomatic patients and in 4 cases with hepatic form. These results agree with those reported in other case studies. The EEG records were abnormal only in 3 cases. Nevertheless, the most interesting finding of this study is the particular frequency (86%) of diffuse or focal decrease of ECD uptake shown by brain SPECT. Conclusion – We highlight the use of this interesting procedure in the therapeutic monitoring of this disease.
Acta Neurologica Scandinavica | 1989
Marcello Giagheddu; G. Puggioni; G. Sanna; G. Tamburini; F. Marrosu; M. G. Rachele; B. Murgia; G. Rosati
ABSTRACT— From 1.1.1958 to 31.12.1986, 110 cases of MG were observed in Sardinia, with a mean annual incidence of 2.5 × 1,000,000 inhabitants and prevalence rates of 7.5, 17.6, 31.4 and 45.0 × 1,000,000 inhabitants respectively (prevalence days: 15.10.1961,24.10.1971,25.10.1981 and 31.12.1986). The disease was found to be more frequent in women. There were no differences in the distribution of MG in various areas of the island. The muscle group more frequently involved at onset was the ocular. In 6.4% of patients an association with thyroid disorders was observed. The mortality of MG patients was significantly higher than expected. Removal of the thymus, carried out in 58 patients, was shown to be useful in the treatment of the disease, particularly in patients without thymomas. No familial cases were observed.
Clinical Genetics | 2008
Paolo Tacconi; Paola Ferrigno; Luigi Cocco; Antonino Carinas; Giorgio Tamburini; P. Bergonzi; Marcello Giagheddu
Sclerosteosis is a rare genetic disorder of bone modelling, similar to, but distinct from, van Buchem disease; it has been described almost exclusively in Afrikaners of South Africa, a white population of Dutch ancestry. Isolated cases have been reported in a girl in Japan, a boy in Spain, and in multiracial families in Brazil and USA.
Acta Neurologica Scandinavica | 2009
Marcello Giagheddu; V. Mascia; A. Cannas; Maria Immacolata Pirastru; F. Sanna; M. G. Rachele; A. Brundu; B. Murgia
The authors carried out an epidemiologic study on amyotrophic lateral sclerosis in Sardinia for the years 1957 through 1990. The duration of the disease and survival were significantly shorter in bulbar form. The distribution of ALS in various areas of the island was found to be not at all homogeneous. Mean yearly incidence showed no significant variations in the decades 1971–80 and 1981–90. In the last decade, an increase of bulbar forms was observed.
Italian Journal of Neurological Sciences | 1998
M. G. Rachele; V. Mascia; P. Tacconi; N. Dessi; F. Marrosu; Marcello Giagheddu
A conjugal case of amyotrophic lateral sclerosis (ALS) observed in Sardinia, Italy is reported. This is believed to be the ninth such observation described in the literature. The couple had lived together for 38 years in a house adjacent to the distillery they owned. No exogenous factors were revealed which could explain the genesis of the disease in either patients. Particularly, exposure to alcohol does not appear to have been involved in causing ALS. On the basis of statistical and epidemiological evaluations, the most likely explanation is that this association was purely coincidental.
Brain Research | 1997
Francesco Marrosu; Alberto Cozzolino; Monica Puligheddu; Marcello Giagheddu; Gaetano Di Chiara
Abstract Hippocampal θ activity was acquired and processed off-line from digitized EEG recordings after subcutaneous (s.c.) administration of the non-opioid δ agonist BW 373U86 (0.5–2.5 mg/kg) in freely-moving rats. Relative θ power spectral analysis, implemented by a signal processing software, showed that BW 373U86 induced a dose-dependent increase in the slow component of θ band (Type 2 θ), while movement-related fast θ band (Type 1 θ) failed to show significant changes. Moreover, the increase in relative Type 2 θ power showed a maximal change at 1 mg/kg of BW 373U86, while higher doses, although effective in increasing relative Type 2 θ, induced locomotion and irregularly increased Type 1 hippocampal θ activity. The administration of 10.0 mg/kg of the δ antagonist Naltrindole (NLI) 30 min before BW 373U86, abolished hippocampal Type 2 θ increase. The rise of relative Type 2 θ power induced by BW 373U86 (1–2.5 mg/kg) was greatly attenuated by 0.1 mg/kg of the selective dopamine (DA) D1 antagonist SCH 23390. Administration of 0.1 mg/kg of SCH 23390 alone did not modify hippocampal Type 2 θ. These results indicate that δ receptors modulate the expression of hippocampal Type 2 θ and dopamine, through D1 receptors, exerts a permissive role on this influence.